WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341388

CAS#: 111490-36-9

Description: Zeniplatin is a biochemical.

Chemical Structure

CAS# 111490-36-9

Theoretical Analysis

MedKoo Cat#: 341388
Name: Zeniplatin
CAS#: 111490-36-9
Chemical Formula: C11H18N2O6Pt
Exact Mass: 469.0813
Molecular Weight: 469.357
Elemental Analysis: C, 28.15; H, 3.87; N, 5.97; O, 20.45; Pt, 41.56

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Zeniplatin; Zeniplatinum.

IUPAC/Chemical Name: Platinum, (2,2-bis(aminomethyl)-1,3-propanediol-N,N')(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)-


InChi Code: InChI=1S/C6H8O4.C5H12N2O2.Pt/c7-4(8)6(5(9)10)2-1-3-6;6-1-5(2-7,3-8)4-9;/h1-3H2,(H,7,8)(H,9,10);6-9H,1-4H2;/q;-2;+4/p-2

SMILES Code: C1CC2(C1)C(=O)[O-][Pt+2]3(NCC(CN3)(CO)CO)[O-]C2=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 469.357 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Aamdal S, Bruntsch U, Kerger J, Verweij J, ten Bokkel Huinink W, Wanders J, Rastogi R, Franklin HR, Kaye SB. Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity. Cancer Chemother Pharmacol. 1997;40(5):439-43. PubMed PMID: 9272122.

2: Olver I, Green M, Peters W, Zimet A, Toner G, Bishop J, Ketelbey W, Rastogi R, Birkhofer M. A phase II trial of zeniplatin in metastatic melanoma. Am J Clin Oncol. 1995 Feb;18(1):56-8. PubMed PMID: 7847260.

3: DeMarco LC, Budman DR, Lathia C, Amorusi P, Birkhofer M, Lichtman S, Weiselberg L, Vinciguerra V, Lovecchio J, Gal D, et al. Pharmacokinetic evaluation of zeniplatin in humans. Cancer Chemother Pharmacol. 1995;36(1):35-40. PubMed PMID: 7720173.

4: Sorensen JB. Treatment of non-small cell lung cancer: new cytostatic agents. Lung Cancer. 1993 Dec;10(3-4):173-87. Review. PubMed PMID: 8075965.

5: Markman M, DeMarco LC, Birkhofer M, Budman D, Hakes T, Reichman B, Rubin S, Jones W, Barakat R, Curtin J, et al. Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy. J Cancer Res Clin Oncol. 1993;119(4):234-6. PubMed PMID: 8423199.

6: Willemse PH, Gietema JA, Mulder NH, de Vries EG, Meijer S, Bouma J, Birkhofer M, Rastogi RB, Sleijfer DT. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex. Eur J Cancer. 1993;29A(3):359-62. PubMed PMID: 8398335.

7: Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 1992 Dec 15;52(24):6885-9. PubMed PMID: 1458477.

8: Christian MC. The current status of new platinum analogs. Semin Oncol. 1992 Dec;19(6):720-33. Review. PubMed PMID: 1462169.

9: Aamdal S. Can ondansetron hydrochloride (Zofran) enhance the nephrotoxic potential of other drugs? Ann Oncol. 1992 Nov;3(9):774. PubMed PMID: 1450070.

10: Dodion PF, de Valeriola D, Crespeigne N, Kantrowitz JD, Piccart M, Wery F, Kerger J, Egorin MJ, Forrest A, Bachur NR, et al. Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. Ann Oncol. 1991 Sep;2(8):589-96. PubMed PMID: 1793726.

11: Bitha P, Carvajal SG, Citarella RV, Child RG, Delos Santos EF, Dunne TS, Durr FE, Hlavka JJ, Lang SA Jr, Lindsay HL, et al. Water-soluble third generation antitumor platinum complexes, [2,2-bis (aminomethyl)-1,3-propanediol-N,N']-[1,1-cyclobutanedicarboxylato (2-)-O,O']platinum(II) and [1,1-cyclobutanedicarboxylato(2-)-O,O'] [tetrahydro-4H-pyran-4,4-dimethanamine-N,N']platinum(II). J Med Chem. 1989 Aug;32(8):2015-20. PubMed PMID: 2754720.

12: CL 287,110 and CL 286,558. Cancer Invest. 1989;7(5):537. PubMed PMID: 2620257.